ERYTECH announces positive DSMB review of its Phase IIb study in Acute Myeloid Leukemia

ERYTECH announces that an independent Data and Safety Monitoring Board (DSMB) completed its first assessment of the company’s Phase IIb study in Acute Myeloid Leukemia (AML) study and unanimously recommended continuation of the trial without modification.

Menu